Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Europe. The aim of this study is to investigate Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in daily Practice.
Interventions
DRUGliraglutide
No treatment given.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011
Exclusion criteria
* None. Available data from all eligible patients for each center, will be included
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of patients achieving HbA1c reduction of at least 1%-point | Week 0, week 52 |
Secondary
| Measure | Time frame |
|---|---|
| Change in body weight | Week 0, week 104 |
| Frequency of patients achieving HbA1c reduction of at least 1%-point | After 4 and 24 months of treatment |
| Frequency of patients achieving HbA1c target (<=7%) | After 4, 12 and 24 months |
| Change in HbA1c (Glycosylated haemoglobin)) | Week 0, week 104 |
| Frequency of patients achieving the composite endpoint consisting in: HbA1c reduction of at least 1%-point and body weight reduction of at least 3% | After 4, 12 and 24 months |
| Percentage of treatment discontinuation for any reason | At 4, 12 and 24 months |
| Changes in blood pressure and lipid profile | Week 0, week 104 |
| Frequency of patients achieving a body weight reduction of at least 3% | After 4, 12 and 24 months |
Countries
Italy
Outcome results
None listed